Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. (ONC) reported a profitable Q3. Total revenues were $1,412,284 for the three months ended September 30, 2025, driven by product revenue of $1,395,013. Net income was $124,841, a clear turnaround from a loss a year ago, as gross profit rose to $1,215,774 and operating income reached $163,114.
Cash generation was strong with year‑to‑date operating cash flow of $710,233, lifting cash and cash equivalents to $4,036,868. The company monetized future IMDELLTRA royalties, receiving $885,000 upfront from Royalty Pharma, recorded as a royalty sale liability with a 6.4% effective annual rate. BRUKINSA led product sales at $1,040,691 in the quarter, followed by TEVIMBRA at $190,623. Short‑term debt stood at $813,296 and long‑term debt at $139,571. Shares outstanding were 1,438,553,263 as of November 1, 2025.
BeOne Medicines Ltd. (ONC) filed an 8-K announcing its third-quarter 2025 results. The company reported that it announced financial results for the three months ended September 30, 2025, and furnished a related press release as Exhibit 99.1 titled “BeOne Medicines Announces Third Quarter 2025 Financial Results and Business Updates.”
The information provided under Item 2.02 is being furnished and is not deemed “filed” under the Exchange Act. The filing also lists the company’s securities, including American Depositary Shares trading on Nasdaq under ONC, with each ADS representing 13 ordinary shares; the ordinary shares are listed on the Stock Exchange of Hong Kong under 06160.
BeOne Medicines Ltd. reporting person Lee Chan Henry (SVP, General Counsel) disclosed multiple transactions in American Depositary Shares (ADS) and options on 10/08/2025. The filing shows several sales under a Rule 10b5-1 plan adopted 05/14/2025, including weighted-average sale prices around $350 and $351. Offsetting purchases and transfers of ADS occurred the same day at prices between $159.03 and $213.32. After those transactions the reporting person holds 9,559 ADS equivalent and direct beneficial ownership in 223,106 ordinary shares. The report also discloses exercise/vesting schedules for outstanding options totaling 127,062 ordinary shares exercisable through 06/04/2034, with stated exercise prices shown in the filing.
BeOne Medicines Ltd. (BEIGF) filed a Form 144 notice reporting a proposed sale of 13,659 ADS through Morgan Stanley Smith Barney LLC on 10/08/2025, with an aggregate market value of $4,666,187.58 and 54,564,278 ADS outstanding. The filing shows the securities were acquired partly by exercise of stock options on 10/08/2025 (12,547 ADS, cash payment) and partly from restricted stock units on 07/29/2025 (1,112 ADS). The filer also disclosed three sales in the prior three months under Rule 10b5-1 and an individual sale: 09/10/2025 (10,006 ADS, $3,257,289.02), 08/13/2025 (9,342 ADS, $2,805,905.17), and 07/30/2025 (920 ADS, $280,232.74). The filer attests there is no undisclosed material adverse information and references potential reliance on a Rule 10b5-1 plan.
John Oyler, Chief Executive Officer and Director of BeOne Medicines Ltd. (ONC), reported sales of American Depositary Shares on 09/16/2025 under a Rule 10b5-1 trading plan adopted on March 12, 2025. The Form 4 lists six sale transactions totaling 28,203 ADS at weighted-average prices ranging approximately from $323.61 to $327.78 (footnotes provide per-transaction ranges). Each ADS represents 13 ordinary shares. The filing shows multiple pools of ordinary shares held directly or indirectly through trusts and entities, with the reporting person disclaiming beneficial ownership of certain holdings. The form is signed by an attorney-in-fact on behalf of the reporting person.
BeOne Medicines Ltd. (BEIGF) filed a Form 144 notifying a proposed sale of 1,204 ADS expected to be sold on September 16, 2025 on NASDAQ with an aggregate market value of $400,053.08. The shares were originally acquired as founders' shares on November 24, 2010. The filing also discloses multiple Rule 10b5-1 sales during the past three months by related parties, including John Oyler and the Pan-Oyler Foundation, with recent individual sales on 07/09/2025 (27,802 ADS, $7,044,590.31) and other sales in June–July 2025 totaling several million dollars in gross proceeds. The filer affirms no undisclosed material adverse information and references Rule 10b5-1 plan representation.
BeOne Medicines Ltd. (BEIGF) insider filing shows a proposed sale of 27,803 ADS through Morgan Stanley Smith Barney, with an aggregate market value of $9,238,102.81 and approximately 54,564,278 ADS outstanding. The securities were acquired as Restricted Stock Units on 04/30/2022. The filer reported multiple Rule 10b5-1 sales in the past three months: 27,802 ADS on 07/09/2025 for $7,044,590.31; 1,661 ADS on 07/08/2025 for $406,520.95; 3,174 ADS on 06/23/2025 for $830,359.98; and 1,460 ADS on 06/17/2025 for $374,473.21, totaling 34,097 ADS sold for $8,655,944.45. The notice states the seller represents no undisclosed material adverse information and references reliance on Rule 10b5-1 where applicable.